Literature DB >> 19185615

Neuropsychological findings in patients with Unverricht-Lundborg disease.

Edoardo Ferlazzo1, Antonella Gagliano, Tiziana Calarese, Adriana Magaudda, Pasquale Striano, Lara Cortese, Clemente Cedro, Virgilie Laguitton, Placido Bramanti, Marilena Carbonaro, Addolorata Albachiara, Nina Fragassi, Domenico Italiano, Edoardo Sessa, Antonietta Coppola, Pierre Genton.   

Abstract

The aims of this study were to clarify if patients with Unverricht-Lundborg disease (ULD) have adequate cognitive functioning and to delineate their neuropsychological profile. We evaluated 20 patients with ULD and 20 healthy, matched controls. Mean age of the patients was 35 years, and mean duration of disease, 22 years. Patients underwent a neuropsychological battery exploring intelligence, executive functions, visuospatial and verbal memory, depression, and anxiety. Eleven of 20 subjects with ULD had mild to moderate cognitive impairment. Compared with controls, patients with ULD had lower scores on all short-term memory and executive function tasks. Linear regression analysis disclosed significant associations between impaired performance on some memory tests and duration of disease and between severity of myoclonus and performance on most executive function tests. In conclusion, most patients with ULD seem to be impaired with respect to cognitive abilities. Longitudinal prospective studies are needed to confirm and further expand our findings.

Entities:  

Mesh:

Year:  2009        PMID: 19185615     DOI: 10.1016/j.yebeh.2009.01.001

Source DB:  PubMed          Journal:  Epilepsy Behav        ISSN: 1525-5050            Impact factor:   2.937


  7 in total

1.  Fronto-striatal dysfunction in type 3 familial cortical myoclonic tremor epilepsy occurring during aging.

Authors:  Eloi Magnin; Marie Vidailhet; Ilham Ryff; Sabrina Ferreira; Pierre Labauge; Lucien Rumbach
Journal:  J Neurol       Date:  2012-06-27       Impact factor: 4.849

Review 2.  The best evidence for progressive myoclonic epilepsy: A pathway to precision therapy.

Authors:  Alessandro Orsini; Angelo Valetto; Veronica Bertini; Mariagrazia Esposito; Niccolò Carli; Berge A Minassian; Alice Bonuccelli; Diego Peroni; Roberto Michelucci; Pasquale Striano
Journal:  Seizure       Date:  2019-08-23       Impact factor: 3.184

Review 3.  Update on Pharmacological Treatment of Progressive Myoclonus Epilepsies.

Authors:  Edoardo Ferlazzo; Dorothee Kasteleijn-Nolst Trenite; Gerrit-Jan de Haan; Felix Felix Nitschke; Saija Ahonen; Sara Gasparini; Berge A Minassian
Journal:  Curr Pharm Des       Date:  2017       Impact factor: 3.116

Review 4.  Psychosocial aspects of epilepsy: a wider approach.

Authors:  Marco Mula; Josemir W Sander
Journal:  BJPsych Open       Date:  2016-08-17

Review 5.  Diabetes: Oral Health Related Quality of Life and Oral Alterations.

Authors:  Gabriele Cervino; Antonella Terranova; Francesco Briguglio; Rosa De Stefano; Fausto Famà; Cesare D'Amico; Giulia Amoroso; Stefania Marino; Francesca Gorassini; Roberta Mastroieni; Cristina Scoglio; Francesco Catalano; Floriana Lauritano; Marco Matarese; Roberto Lo Giudice; Enrico Nastro Siniscalchi; Luca Fiorillo
Journal:  Biomed Res Int       Date:  2019-03-18       Impact factor: 3.411

Review 6.  Cognitive Dysfunction in Repeat Expansion Diseases: A Review.

Authors:  Sizhe Zhang; Lu Shen; Bin Jiao
Journal:  Front Aging Neurosci       Date:  2022-04-11       Impact factor: 5.750

7.  3D texture analysis reveals imperceptible MRI textural alterations in the thalamus and putamen in progressive myoclonic epilepsy type 1, EPM1.

Authors:  Sanna Suoranta; Kirsi Holli-Helenius; Päivi Koskenkorva; Eini Niskanen; Mervi Könönen; Marja Äikiä; Hannu Eskola; Reetta Kälviäinen; Ritva Vanninen
Journal:  PLoS One       Date:  2013-07-29       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.